Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma
Top Cited Papers
Open Access
- 10 March 2011
- journal article
- review article
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 32 (11), 1978-1985
- https://doi.org/10.3174/ajnr.a2397
Abstract
The current standard of care for newly diagnosed cases of high-grade glioma is surgical resection followed by RT with concurrent chemotherapy. The most widely used criteria for assessing treatment response are based on a 2D measurement of the enhancing area on MR imaging known as the Macdonald Criteria. Recently, nontumoral increases (pseudoprogression) and decreases (pseudoresponse) in enhancement have been found, and these can confuse outcome evaluation. Here we review pseudoprogression and pseudoresponse and describe how better understanding of these phenomena can aid interpretation.Keywords
This publication has 34 references indexed in Scilit:
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working GroupJournal of Clinical Oncology, 2010
- Pseudoprogression and pseudoresponse in the treatment of gliomasCurrent Opinion in Neurology, 2009
- Response criteria for gliomaNature Clinical Practice Oncology, 2008
- Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomideCancer, 2008
- Clinical features, mechanisms, and management of pseudoprogression in malignant gliomasThe Lancet Oncology, 2008
- Clinical and radiographic features of peritumoral infarction following resection of glioblastomaNeurology, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005
- Immediate post-radiotherapy changes in malignant glioma can mimic tumor progressionNeurology, 2004
- Malignant Gliomas: MR Imaging Spectrum of Radiation Therapy- and Chemotherapy-induced Necrosis of the Brain after TreatmentRadiology, 2000
- Response criteria for phase II studies of supratentorial malignant glioma.Journal of Clinical Oncology, 1990